STOCK TITAN
  1. Home
  2. MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

MACK NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
1 253 sessions, May 24, 2023 to May 24, 2024
Largest daily move
+7.2% close of February 13, 2024
1-year change
+21.3% closing prices, May 24, 2023 to May 24, 2024
5-year change
+208.7% closing prices, May 24, 2019 to May 24, 2024

Company Description

Merrimack Pharmaceuticals (NASDAQ: MACK) is classified in the pharmaceutical preparations industry and carries a market capitalization of $223.7M.

MACK has gained 21.3% over the past year. The last closing price was $15.13.

This page collects what Stock Titan holds for MACK, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
+21.3%
Performance 1 year
$223.7M
Market Cap
14.8M
Shares outstanding

Merrimack Pharmaceuticals (MACK) closed at $15.13 on May 24, 2024. Over the past 12 months, the price has gained 21.3%.

See what a $1,000 investment in MACK would be worth today

MACK Metrics & Rankings

Market Cap
$223.7M
View ranking
Month to date
+2.6%
View ranking
YTD
+12.8%
View ranking

Price returns through May 24, 2024. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
-0.13%

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

dividends
+0.27%

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

dividends
+1.63%

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

+0.14%

Merrimack Receives $225 Million Milestone Payment from Ipsen

-0.34%

Merrimack Reports Full Year 2023 Financial Results

earnings
-2.20%

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

fda approval
+1.13%

Merrimack Reports Third Quarter 2023 Financial Results

earnings
+0.17%

Merrimack Reports Second Quarter 2023 Financial Results

earnings
+0.79%

Merrimack Reports First Quarter 2023 Financial Results

earnings
-0.26%

Merrimack Reports Full Year 2022 Financial Results

earnings

Merrimack Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include dividends, earnings, fda approval. View all MACK news →

SEC Filings

View All

No SEC filings available for MACK.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

MACK Company Profile & Sector Positioning

Merrimack Pharmaceuticals (MACK) and is listed on the NASDAQ.

Frequently Asked Questions

What is the current stock price of Merrimack Pharmaceuticals (MACK)?

The current stock price of Merrimack Pharmaceuticals (MACK) is $15.13 as of July 18, 2024.

What is the market cap of Merrimack Pharmaceuticals (MACK)?

The market cap of Merrimack Pharmaceuticals (MACK) is approximately $223.7M. Learn more about what market capitalization means .